Update on the Detection of the latest SARS-CoV-2 Variant-LP.8.1
The Level of Action: Green Green border means the letter is for information only. Singapore, February 14, 2025 – Update on the Detection of the latest SARS-CoV-2 Variant Credo Diagnostics Biomedical Pte. Ltd. is committed to the post-market monitoring of the reliability of our assays. We have performed nucleotide analysis using the BLASTn method comparing […]
Update on the Detection of the latest SARS-CoV-2 Variant
The Level of Action: Green Green border means the letter is for information only. Singapore, September 24, 2024 – Update on the Detection of the latest SARS-CoV-2 Variant Credo Diagnostics Biomedical Pte. Ltd. is committed to the post-market monitoring of the reliability of our assays. We have performed nucleotide analysis using the BLASTn method comparing […]
Update on Detection of Existing Influenza A Variant
The Level of Action: Green Green border means the letter is for information only. Singapore, June 12, 2024 – Update on Detection of Existing Influenza A Variant Credo Diagnostics Biomedical Pte. Ltd. is committed to the post-market monitoring of the reliability of our assays. We have performed nucleotide analysis using the BLASTn method comparing primers […]
Update on Detection of Existing Influenza A Variant
Singapore, December 6, 2023 – Update on the Detection of Existing Influenza A Variant Credo Diagnostics Biomedical Pte. Ltd. is committed to the post-market monitoring of the reliability of our assays. We have performed nucleotide analysis using the BLASTn method, comparing primers and probes of the assays involving influenza A virus detection to all sequences […]
Update on Detection of the Latest SARS-CoV-2 Variant BA.2.86
Singapore, September 7, 2023 – Update on Detection of the Latest SARS-CoV-2 Variant Credo Diagnostics Biomedical Pte Ltd is committed to the post-market monitoring of the reliability of our assays. We have performed nucleotide analysis using the BLASTn method, comparing primers and probes of the assays involving SARS-CoV-2 virus detection to all sequences listed in […]
Update on Detection of the Iatest Influenza A subtypes
Singapore, April 21, 2023 – Update on Detection of the Influenza A subtypes. Credo Diagnostics Biomedical Pte. Ltd. is committed to the post-market monitoring of the reliability of our assays. We have performed nucleotide analysis using the BLASTn method, comparing primers and probes of the assays involving Influenza A virus detection to the sequences of […]
Update on Detection of the latest SARS-CoV-2 Variant
Singapore, April 11, 2023 – Update on Detection of the latest SARS-CoV-2 Variant Credo Diagnostics Biomedical Pte Ltd continues the post-market monitoring of the reliability of our assays. We have performed nucleotide analysis using BLASTn analysis comparing primers and probes of the assays involving SARS-CoV-2 virus detection to the sequences listed in GISAID from January […]
Update on Detection of the Influenza A subtypes
Singapore, March 2nd, 2023 – Update on Detection of the Influenza A subtypes. Credo Diagnostics Biomedical Pte. Ltd. is committed to the post-market monitoring of the reliability of our assays. We have performed nucleotide analysis using the BLASTn method, comparing primers and probes of the assays involving Influenza A virus detection to the sequences of […]
VitaPCR™ Assays Enable Detection of the latest SARS-CoV-2 Variant Strain
Singapore, February 9, 2023 – Detection of the latest SARS-CoV-2 Variant Strain In response to the rise of new Covid-19 variants, Credo Diagnostics Biomedical Pte Ltd continues to ensure the effectiveness of our assays using BLASTn analysis. (with the oligonucleotide primers and probes of the assays involving SARS-CoV-2 detection) against the sequences listed in GISAID from September 1st, […]
Extension of the distribution agreement between Credo Diagnostics Biomedical Pte Ltd and BIOSYNEX S.A.
BIOSYNEX (ISIN : FR0011005933, Mnémonique :ALBIO), a major player in public health, announces the extension of its partnership with the Singaporean company Credo Diagnostics Biomedical Pte Ltd (“Credo Diagnostics”). The collaboration between the two companies had started at the beginning of the Covid-19 health crisis in March 2020, which eventually led to an agreement to […]
